Progen Industries (ASX: PGL, NASDAQ: PGLAF) is scheduled to meet with the FDA on 5 April to discuss the design of current clinical trials with PI-88 (the company’s most advanced clinical compound) as well as the strategy for future trials. The design of new protocols is important in establishing the potential route to market for PI-88 and as such Progen has maintained an active relationship with the FDA through its Phase II trial program
